NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy W Wang, AK Erbe, JA Hank, ZS Morris, PM Sondel Frontiers in immunology 6, 155000, 2015 | 644 | 2015 |
Neuroblastoma patients' KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children's Oncology Group AK Erbe, W Wang, L Carmichael, KM Kim, EA Mendonça, Y Song, D Hess, ... Clinical Cancer Research 24 (1), 189-196, 2018 | 58 | 2018 |
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion W Wang, AK Erbe, KA Alderson, E Phillips, M Gallenberger, J Gan, ... Cancer Immunology, Immunotherapy 65, 1047-1059, 2016 | 44 | 2016 |
Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment W Wang, A Uberoi, M Spurgeon, E Gronski, V Majerciak, A Lobanov, ... PLoS Pathogens 16 (1), e1008206, 2020 | 34 | 2020 |
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab AK Erbe, W Wang, L Carmichael, A Hoefges, B Grzywacz, PK Reville, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 25 | 2019 |
Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical Cancer W Wang, X Zhang, M Li, C Hao, Z Zhao, H Liang Clinica Chimica Acta 483, 249-255, 2018 | 23 | 2018 |
HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy AK Erbe, W Wang, PK Reville, L Carmichael, KM Kim, EA Mendonca, ... Frontiers in immunology 8, 675, 2017 | 21 | 2017 |
FCGR polymorphisms influence response to IL2 in metastatic renal cell carcinoma AK Erbe, W Wang, J Goldberg, M Gallenberger, KM Kim, L Carmichael, ... Clinical Cancer Research 23 (9), 2159-2168, 2017 | 19 | 2017 |
Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy W Wang, AK Erbe, KB DeSantes, PM Sondel Future Oncology 13 (12), 1043-1047, 2017 | 18 | 2017 |
Stress keratin 17 expression in head and neck cancer contributes to immune evasion and resistance to immune-checkpoint blockade W Wang, T Lozar, AE Golfinos, D Lee, E Gronski, E Ward-Shaw, M Hayes, ... Clinical Cancer Research 28 (13), 2953-2968, 2022 | 16 | 2022 |
Genotyping single nucleotide polymorphisms and copy number variability of the FCGRs expressed on NK cells AK Erbe, W Wang, M Gallenberger, JA Hank, PM Sondel Natural Killer Cells: Methods and Protocols, 43-56, 2016 | 14 | 2016 |
Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2 W Wang, AK Erbe, M Gallenberger, KM Kim, L Carmichael, D Hess, ... Cancer Immunology, Immunotherapy 65, 1523-1532, 2016 | 10 | 2016 |
Stress keratin 17 and estrogen support viral persistence and modulate the immune environment during cervicovaginal murine papillomavirus infection W Wang, ME Spurgeon, A Pope, S McGregor, E Ward-Shaw, E Gronski, ... Proceedings of the National Academy of Sciences 120 (12), e2214225120, 2023 | 9 | 2023 |
Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial AK Erbe, W Wang, L Carmichael, KM Kim, PK Reville, WB London, ... Cancer Research 77 (13_Supplement), LB-048-LB-048, 2017 | 6 | 2017 |
Specific KIR and HLA genotypes affect outcomes of single-agent anti-CD20 immunotherapy of follicular lymphoma B Grzywacz, AK Erbe, W Wang, EA Ranheim, JA Hank, KM Kim, ... Blood 122 (21), 507, 2013 | 6 | 2013 |
Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C AK Erbe, W Wang, B Grzywacz, EA Ranheim, JA Hank, K Kim, ... Journal for ImmunoTherapy of Cancer 1, 1-1, 2013 | 5 | 2013 |
Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond T Lozar, I Laklouk, AE Golfinos, N Gavrielatou, J Xu, C Flynn, A Keske, ... Cancers 15 (19), 4905, 2023 | 1 | 2023 |
Certain KIR/KIR ligand genotypes influence patient response to immunotherapy in neuroblastoma patient PM Sondel, AK Erbe, W Wang, L Carmichael, A Hoefges, KM Kim, ... Journal for ImmunoTherapy of Cancer 5, 2017 | 1 | 2017 |
Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial. AK Erbe, W Wang, L Carmichael, KM Kim, EA Mendonca, Y Song, D Hess, ... Journal of Clinical Oncology 34 (15_suppl), e14014-e14014, 2016 | 1 | 2016 |
Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2) AK Erbe, W Wang, KM Kim, L Carmichael, MI Gallendberger, D Hess, ... Journal for ImmunoTherapy of Cancer 3 (2), 1-2, 2015 | 1 | 2015 |